menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Progress with CRISPR/Cas9 at the American Society of Gene & Cell Therapy Annual Meeting

First-time data validates high levels of gene editing and reduction in serum transthyretin protein levels in rat models First to demonstrate single-dose, in vivo results using proprietary lipid nanoparticle delivery system in mice showing: approximately 97 percent reduction in serum transthyretin
Read More

Intellia Therapeutics Announces First Quarter 2017 Financial Results

First to demonstrate single dose, in vivo results using a proprietary lipid nanoparticle delivery system showing: approximately 97 percent reduction in serum transthyretin protein levels; 70 percent liver editing efficiency following a single dose; six months post-single-dose durability of stable
Read More

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

CAMBRIDGE, Mass., Basel, Switzerland, April 26, 2017, (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the United States Patent
Read More

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision

Appeal to the U.S. Court of Appeals for the Federal Circuit seeks review and reversal of the Patent Trial and Appeals Board’s decision to terminate CRISPR/Cas9 interference In parallel, the companies and their licensors plan to pursue additional patents in the U.S.
Read More

Intellia Therapeutics Announces European Patent Office’s Decision to Grant CRISPR/Cas9 Genome Editing Technology Patent

Patent covers foundational CRISPR/Cas9 inventions that Intellia sublicensed for use in human therapeutics Patent covers compositions of CRISPR single guide RNA technology for use in non-cellular and cellular settings, including eukaryotic cells CAMBRIDGE, Mass.
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results

First to demonstrate single dose, in vivo results, showing approximately 97 percent reduction in serum transthyretin protein levels Further established a comprehensive platform, including a proprietary lipid nanoparticle delivery system, to accelerate therapeutic development Executed partnering
Read More

Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology

First to demonstrate single dose, in vivo results, showing approximately a 97 percent reduction in serum transthyretin protein levels Durability data show stable liver editing for at least four months Increased liver editing efficiency reported to date at 70 percent, following a single dose
Read More

Intellia Therapeutics to Present at March Investor Healthcare Conferences

CAMBRIDGE, Mass. , March 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that company senior leaders will present at key March investor
Read More

Intellia Therapeutics to Hold Conference Call to Address Patent Interference Proceedings

CAMBRIDGE, Mass. , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer
Read More

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Provide Update on CRISPR/Cas9 U.S. Patent Interference Proceedings and Grants of Corresponding Patents in the U.K.

UC’s patent application covering the use of CRISPR/Cas9 genome editing technology with a single-guide RNA format in any non-cellular or cellular setting, including human and other eukaryotic cells, will be released from the interference absent an appeal, and may then be prosecuted to potential
Read More
RSS FEEDS
PRINT PAGE